Advances in Bioprocessing Industry case studies on single-use, flexible and continuous bioprocessing

Dr. Zhou currently is the Director of Biologics at Wuxi Apptec. He leads a team for perfusion process development of recombinant protein and mAb-based biotherapeutics, from R&D to GMP-compliant production scale, overcoming the challenge of long-term continuous perfusion culture with high cell-density, obtaining stable and good product quality. Before joining Wuxi Apptec, Dr.Zhou worked at commercial cell culture process development department of Genzyme Corporation, and participated in perfusion cell culture process development works of a series of enzyme and mAb-based pharmaceuticals. Dr. Zhou graduated from Chemical Engineering Department of Tsinghua University, and holds Ph.D. in chemical engineering from MIT.

Dr. Lin is currently the Director of Downstream Process Developing at CGB/ChemPartner. He brings 10 years’ experience of in biologics development and manufacturing with Assay development, fermentation, purification and formulation. Dr. Lin has set up PD/AD/QC labs and pilot/commercial single-use systems from 50L up to 2K. He previously held roles at JHL Biotech, PharmaEssentia, Purzer Pharmaceuticals and YungShin Pharma. Dr. Lin holds a Bachelor’s of Science degree from National Chung Hsing University, a Master’s in Chemical Engineering from Chung Yuan Christian University and a Ph.D. in Chemical Engineering from National Taiwan University.

Mr. Audouy is currently Asia Sales Director for Repligen. Based out of Singapore, he supports the rapidly expanding Asian market as the Repligen leading product portfolio continues to expand. Mr. Audouy began working in the bioprocess industry in 2002 and has worked with various technologies and has previously held roles at Constant Systems Ltd and Refine Technology.  Mr. Audouy graduated from the Daventry Campus of Northampton College, Northants, UK with A-Levels in Physics, Electronics, French and English Literature.

Mr. Gao is currently the Process Manager for GMP production process development and pilot production of plasmid, lentivirus and CAR-T cells at the Suzhou Ctigen Medical Technology Co., Ltd.  He brings 13 years’ experience of downstream biotherapeutic process development, pilot scale-up, technology transfer and CMO production (especially in CAR-T, monoclonal antibody, cell factors), participated in production technology transfer for Australia, India and England clinical trial applications, and has spent several years in team management. Mr.Gao previously held roles at JW Biotechnology, BioMabs and Jintao Biotechnology of Northern China Pharmaceutical group. Mr. Gao holds MSc in biochemical engineering from East China University of Science and Technology

Mr. Guodong Chang is currently the Vice Director of National Engineering Laboratory of Anti-cancer protein drugs and also the CEO of Beijing Protgen Bioscience development Co.,Ltd., and it’s related companies. Mr. Chang has 20 years experiences of biotechnology and biopharmaceutical development, especially in recombinant protein therapeutics research and production application development. As leading scientist, developed several new drugs, which are successfully approved by China and/or EU market.

Mr. Bianchi is currently the Field Applications Specialist for Repligen downstream TFF products. He brings over 20 years of experience in process filtration and separation with a significant portion of that time focused on Tangential Flow Filtration applications utilizing flat sheet cassettes and hollow fiber modules. Mr. Bianchi has held various technical positions supporting Pall Corporation, Spectrum Laboratories, FloDesign Sonics and TangenX™. He holds a Bachelor of Science degree in Chemistry from Worcester Polytechnic Institute.